From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Psychiatry>
  4. Summary and Comment

Tamoxifen for Mania: Maybe It’s Not Just for Breast Cancer

Results from a small pilot study are promising.

Acute mania is treated with antipsychotics and with mood stabilizers (lithium and the anticonvulsants valproate and carbamazepine). Identifying the biochemical targets of these medications has been challenging. A recent hypothesis is that the protein kinase C (PKC) signaling cascade is a target of the mood stabilizers. This is supported by gene studies and animal models, suggesting that PKC activation is associated with mania-like behavior. PKC inhibitors block acute responses to cocaine and reduce risk-taking behavior. Tamoxifen, a nonsteroidal antiestrogen used to treat breast cancer, is a potent and selective PKC inhibitor that crosses the blood-brain barrier.

Investigators previously conducted a single-blind study of tamoxifen in acute mania. Now, in a double-blind study, they followed 16 inpatients (14 men; average age, 35) who had a diagnosis of bipolar disorder with a current manic or mixed episode. After a 2- to 7-day screening period and discontinuation of all medications except benzodiazepines, patients were randomized to 3 weeks of tamoxifen (20–140 mg/day) or placebo. The tamoxifen group showed significant improvement in mania starting on day 5 and continuing through day 21. Mania scores improved by more than 50% in five of eight patients in the tamoxifen group but in only one of eight in the placebo group. Loss of appetite was the only adverse effect that occurred more frequently with tamoxifen than with placebo.

Comment: Because tamoxifen has antiestrogenic as well as PKC-inhibiting effects, we cannot ascribe these therapeutic results to a specific mechanism of action. However, the results are intriguing and warrant replication in larger controlled trials. More specific PKC inhibitors should be developed and tested.

Jonathan Silver, MD

Published in Journal Watch Psychiatry November 5, 2007

Citation(s):

Zarate CA Jr et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 2007 Sep; 9:561.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.